ABSTRACT: Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated combined burden of over 87 million disability-adjusted life years. New drugs are needed for each of these diseases. Building on the previous identification of NEU-617 (1) as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), we have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria). Based on hits identified in this screening campaign, we describe the preparation of several replacements for the quinazoline scaffold and report these inhibitors' biological activities against these parasites. In doing this, we have identified several potent proliferation inhibitors for each pathogen, such as 4-
■ INTRODUCTION
Several tropical diseases are caused by protozoan parasites transmitted by insects. Taken together, malaria (caused by Plasmodium species), human African trypanosomiasis (HAT, caused by Trypanosoma brucei), Chagas disease (caused by T. cruzi), and leishmaniasis (caused by Leishmania species) represent diseases with an estimated combined burden of over 87 million disability-adjusted life years. 1 While progress has certainly been made toward the discovery of new hits, much work remains to translate these hits into promising chemical lead series that may be advanced for drug development.
One pragmatic method for launching such programs is "target repurposing", wherein inhibitors of human homologues of essential parasite proteins are assessed for efficacy against parasite cells. 2 We have recently initiated the repurposing of a variety of kinase inhibitors for parasitic diseases 3−7 and have also described the use of established human phosphodiesterase inhibitors as starting points for lead discovery. 8 We have described the discovery of NEU-617 (1), a derivative of the approved human cancer drug lapatinib (2) , which acts as a potent, orally bioavailable growth inhibitor of T. brucei that showed a modest effect in a mouse model of bloodstream infection. 6 We also reported the association of lapatinib with four trypanosome protein kinases. 9 Based on the close phylogenetic relationship between the kinomes of the trypanosomatid parasites (T. brucei, T. cruzi, and Leishmania major), 10 we hypothesized that all the pathogens would be susceptible to these inhibitors. We have therefore tested 1, along with the other analogs synthesized during the course of our hit-to-lead optimization program, against the two other kinetoplastid parasites. Based on our previous observation that related chemotypes show activity against Plasmodium falciparum, 11 we also screened this set of compounds against cultures of drug-sensitive and drug-resistant strains of malaria. In doing so, we noted differential structure−activity relationships for these compounds' growth inhibitory properties against each of the parasites, thus launching a multiparasite optimization campaign from the same lead series.
In this paper, we describe these cross-pathogen assay results and outline our evaluation of replacements for the quinazoline scaffold of 1 for each of the parasites. We posit that such a cross-screening approach can be a highly fruitful method for identification of new protozoan parasite growth inhibitors.
■ RESULTS
First, in order to ascertain antiparasitic activities of our 66 previously reported analogs, 6 we measured their growth inhibitory activities against T. cruzi (intracellular amastigotes), L. major (promastigote and intracellular amastigote life stages), and P. falciparum (D6, drug sensitive strain). The structures of the most potent compounds for each parasite are shown in Figure 1 and Table 1 , and the complete set of screening data for these is tabulated in the Supporting Information (Tables S1−  S7) .
From these experiments, we observed that 15 morpholinosulfonamide compounds were identified with activity against L. major promastigotes: seven of these were submicromolar inhibitors and two were also submicromolar against intracellular amastigotes (the most relevant life stage for human infections of leishmaniasis). The des-fluoro analog NEU-551 (3) showed the highest activity against promastigotes (EC 50 = 0.50 μM). We initially tested compounds against T. cruzi at a single concentration and found that 32 compounds inhibited proliferation >65% at 10 μM concentrations; of these 32 compounds, the homopiperazinyl sulfonamide-substituted tail was preferred (NEU-628 (4), EC 50 = 0.51 μM). The active compounds against P. falciparum (drug-sensitive D6 strain) all contained a basic nitrogen at the end of the tail group with NEU-627 (5) being the most potent with an EC 50 of 27 nM. Though we note that the number of headgroup replacement analogs tested was far smaller and less diverse than the tail variations, the lapatinib headgroup 3-chloro-4-((3-fluorobenzyl)oxy)aniline showed optimal potency against all of the parasites, except for both Leishmania life stages. Previous efforts focused on the "head" (4-benzyloxyanilines) and "tail" (denoted as R in Figure 1 ) regions of lapatinib, while maintaining the central quinazoline scaffold (highlighted in blue in Figure 1 ). Thus, we planned a broader evaluation of other bicyclic aromatic replacements for the quinazoline scaffold that would test the important features of the chemotype for activity. These scaffold replacements were selected for exploration of the requisite nitrogen atom positioning in the heteroaromatic ring (see the heterocycle precursors highlighted in Figure 2 , dihalides 6−9). In addition, the cyanoquinoline and thienopyrimidine scaffolds (dihalides 10−12) were selected in order to include other established tyrosine kinase inhibitor chemotypes.
12−15 For a matched exploration of these scaffolds, we elected to maintain the four permutations of head/tail combinations that displayed the most potency in each parasite (shown in Figure 1 ) in the new analogs that we prepared.
We first set out to synthesize the requisite dihalogenated scaffolds shown in Figure 2 . The syntheses of 6-and 7-bromo-4-chloroquinolines 6a and 6b were carried out via the Gould− Jacobs sequence following previously reported protocols. 16 A complementary set of 1-aminoisoquinolines was devised to draw out essential interactions with either nitrogen of the quinazoline scaffold. Thus, 7a and 7b were synthesized utilizing known transformations.
17−19 The 6-bromo-4-chlorothienopyrimidines 10 and 11 were prepared as previously reported. 20−25 The requisite cyanoquinoline template 12 was prepared using established protocols similar to that of the 4-chloroquinolines. 26 Though few examples of cinnoline or phthalazine based kinase inhibitors exist in the literature, 27−30 we opted to prepare analogues utilizing both heterocycles to test the required positioning of the two nitrogen atoms on the scaffold. Preparation of 6-bromo-4-chlorocinnoline 8a commenced with the bromination of o-aminoacetophenone 13 followed by diazotization of the amine and in situ cyclization to the 6-bromocinnolin-4(1H)-one 15 (Scheme 1). 31, 32 Chlorination in neat POCl 3 did not give the expected 8a as the major product. Instead, we observed high conversion to 4,6-dichlorocinnoline 8b. We hypothesized that this side reaction occurred via chloride displacement under the acidic conditions of the reaction (Scheme S1, see Supporting Information). A 10:1 product ratio of 8a to 8b could be achieved through the use of THF as solvent and 3 equiv of POCl 3 . The regiomeric 7-bromo-4-chlorocinnoline 8c was prepared in a similar fashion starting instead with the acylation of 3-bromoaniline 16 to 2-amino-4-bromoacetophenone 17, followed by diazotization and chlorination. 33 The 7-bromo-1-chlorophthalazine template 9a was synthesized as shown in Scheme 2. Aryl bromination of phthalide 19 was carried out in acidic medium with NBS to produce a separable mixture of 4-and 6-bromophthalide 20. Benzylic bromination was achieved using a modification of an established procedure, 34 and the resulting dibromides 21a,b were converted to the corresponding bromophthalazinone 22 upon treatment with hydrazine. As with 15, 22a was converted to the dichlorinated side product 9b on treatment with neat POCl 3 , though dilution minimized this side reaction. Acetonitrile with 3 equiv of POCl 3 provided a >10:1 ratio of the desired chlorination product 9a. The 6-bromo-1-chlorophthalazine scaffold 9c could be synthesized in an identical manner starting with the commercially available 5-bromophthalide 20b.
Amination of the dihalogenated quinoline, isoquinoline, cyanoquinoline, and thienopyrimidine scaffolds was carried out by applying methods similar to those we previously reported (Scheme 3). 6 However, low yields (∼20%) resulted when these With this set of new analogs that are matched to the previously described antiparasitic agents, 6 we set out measuring these analogs' activities against T. brucei̧, T. cruzi, L. major, and P. falciparum, and counter-screened against host cells (NIH 3T3 and HepG2 cell lines) using assays that we previously reported. 7 The HepG2 data is summarized in Tables 2 and 3 . A small number of compounds showed activity against NIH 3T3 cells; these are summarized in the Supporting Information, Table S8 .
■ DISCUSSION AND CONCLUSIONS
Compound 1 remained the most potent T. brucei growth inhibitor among this set of analogs. A pair of quinoline-based compounds, 50 and 52, each with a basic aliphatic amine on the tail group show double digit nanomolar potency (79 and 87 nM, respectively). The potency of these compounds seems to be driven by the aliphatic amine in the tail region rather than by the placement of nitrogen atoms in the scaffold, because the analogous isoquinoline analogue 58 is approximately equipotent (100 nM) to 50.
The quinoline analogs 50, 51, and 52 displayed submicromolar potency against intracellular amastigotes of T. cruzi. Most other analogs showed a complete loss of activity, perhaps due to issues with penetration into both the host cell and the parasite. (With intracellular parasites, we note that compensating effects from interactions with host cell targets cannot be ruled out.) However, the 3-cyanoquinoline analogue 83, shows a 5-fold improvement in potency over the matched original quinazoline analog 4. In the headgroup region, the 3-fluoro substituent affords a 10-fold increase in potency over the matched des-fluoro analog (cf. 83 vs 84). The quinoline 51 displayed a slight drop in potency compared with the quinazoline 4, and the matched isoquinoline 59 is 10-fold less potent. Taken together with the cyanoquinoline analog 83, this data demonstrates the apparent importance of two H-bond acceptor motifs in the scaffold.
In the case of L. major, 47 showed a 2.5-fold increase in potency from the matched quinazoline analogue 3 (0.20 versus 0.50 μM respectively) against the promastigote life stage of L. major. The corresponding isoquinoline compound 55 showed a complete loss in activity, reinforcing the essentiality of the N1 atom of the quinazoline. Interestingly, there was no activity observed against the amastigote life stage of the parasite for 47. In contrast, the 7-substituted quinoline 52 displayed submicromolar potency against both life stages (0.40 μM against promastigotes and 0.89 μM versus amastigotes). Compared with the quinazoline compound 4, the analogous cinnoline 68 displayed increased potency against amastigotes (0.24 μM) albeit with a significant decrease in potency against the promastigote form. This lack of correlation of compounds between promastigote and amastigote life stages of the parasite has been reported by us and others recently. 7, 35 Other compounds displaying modest potency include 76 and 91, both containing the N-methylhomopiperazinyl sulfonamide tail.
In P. falciparum cultures, three isoquinoline compounds with a basic amine at the terminus of the tail region showed modest potency highlighted by 57 being nearly equipotent to the parent quinazoline 5 (40 vs 27 nM). Though the matching quinoline 49 showed a complete loss in activity, its regioisomer 50 was slightly more active than 5 (EC 50 = 19 nM). The four quinoline analogs without a basic amine on the tail group were within 2-fold of 5 with 48 being the most potent with an EC 50 = 16 nM. Similarly, all four thienopyrimidine analogs with a basic tail group amine (89−92) were potent, within 4-fold of 5. Among these compounds there was no preference for either thienopyridine isomer; the N-methylpiperazinyl tail group was 2.5-to 4-fold more potent than the N-methylhomopiperazinyl tail on each scaffold.
Among the phthalazines, 74 and 76, both with a basic nitrogen on the tail and substituted at the 6-position (regiomeric to 5) were equipotent to 5. Also requiring a basic amine on the tail region, the cinnoline analogs with piperazinyl and homopiperazinyl moieties (65−68) showed modest to high potency against P. falciparum D6 strain. Excitingly, the 7-substituted isomers (66 and 68) were highly potent antiplasmodial agents (14 and 3 nM, respectively). Since we observed that the most potent compounds against P. falciparum were 4-aminoquinolines (similar to the prototypical antimalarial agent chloroquine), we tested them against drug resistant parasite strains W2 and C235. We were gratified to observe that all of the compounds tested are similarly active against drug resistant strains of P. falciparum (Table S9 , Supporting Information), suggesting that despite the shared scaffold, these analogs likely display a mechanism of action or mechanism of resistance that differs from those of chloroquine.
Our studies demonstrate which of these scaffolds are the most promising for further optimization on a parasite-byparasite basis. Figure 3 highlights the range of antiparasite potencies for each scaffold. By inspection, it is clear that the quinoline scaffold is significantly active across all four pathogens. We note that cinnoline (C) and quinoline (A) generally provide the most potent antiplasmodial agents, and the 7-position substitutions are slightly favored in both of these templates. For T. brucei, the 7-substituted quinolines and 6-substituted isoquinolines appear optimal (noting that, despite the differential numbering of the scaffolds, these two particular scaffolds present the same relative regiochemistry). Analogous diagrams for the other pathogens are also provided in Figure 3 (and a diagram for Leishmania promastigotes is in the Supporting Information ( Figure S1 ). A summary of the preferred bicyclic scaffold for each parasite is shown in Figure  3E , noting that none appear to be markedly better than the others against Leishmania intracellular amastigotes.
For all parasites except for T. brucei, we also note a preference for tail substituents with a basic amine present. Considering only the most "potent" compounds (EC 50 ≤ 0.1 μM for the extracellular parasites T. brucei and P. falciparum; EC 50 ≤ 1 μM for the intracellular parasites L. major and T. cruzi), we note that the N-methylpiperizine and N-methylhomopiperazine are preferred among analogs that were tested, over the less-basic morpholine or nonbasic morpholinosulfonamide substituents (Table 4) . At this point, we cannot discern whether this is an effect that is mediated by the biological target(s) involved in proliferation inhibition, by parasite permeation, or by a combination of both; this will be a matter for further investigation.
We have previously observed that molecules bearing these head and tail combinations possess problematic physicochemical properties, likely due to the molecular size and lipophilicity. The intent of the present work was to explore the central scaffold functionality, rather than to address these shortcomings. Nonetheless, we selected five representative compounds from among the most potent to be tested for their physicochemical properties (Table 5) . Not unexpectedly, compounds tested were >99% plasma protein bound with limited thermodynamic aqueous solubility (<1 μM). Such properties are undoubtedly a result of the high molecular weights and clogP values; these issues remain the focus of ongoing efforts, which are now focused on specific scaffolds for each pathogen.
In summary, through a cross-parasite screening campaign of existing quinazoline T. brucei proliferation inhibitors, we uncovered new hits against three other protozoan parasites. Encouraged by that initial success, we focused on exploring the central heterocycle scaffold, an exercise that has uncovered additional highly potent compounds. Scaffold variations have revealed heteroatom positioning essential for activity within this chemotype, while variations to regiochemical attachment points have introduced a new set of regioisomers with multiparasite potency. Thus, we have established a new lead series for each of these protozoan parasites, which can be now advanced in parallel for drug discovery against four different parasitic diseases. With this in mind, further optimization of physicochemical properties and cellular selectivity of each is ongoing, with a specific focus on the "head" and "tail" regions. These results will be reported in due course.
■ EXPERIMENTAL SECTION
Chemical Synthesis. Unless otherwise noted, reagents were obtained from Sigma-Aldrich, Inc. (St. Louis, MO), Fisher Scientific, Frontier Scientific Services, Inc. (Newark, DE), or Matrix Scientific (Columbia, SC) and used as received. Boronic acids and esters and aniline reagents were purchased, except for those whose syntheses are listed in the Supporting Information. Reaction solvents were dried by passage through alumina columns on a purification system manufactured by Innovative Technology (Newburyport, MA). Microwave reactions were performed using a Biotage Initiatior-8 instrument. NMR spectra were obtained with Varian NMR systems, operating at 400 or 500 MHz for 1 H acquisitions as noted. LCMS analysis was performed using a Waters Alliance reverse-phase HPLC, with singlewavelength UV−visible detector and LCT Premier time-of-flight mass spectrometer (electrospray ionization). All newly synthesized compounds that were submitted for biological testing were deemed >95% pure by LCMS analysis (UV and ESI-MS detection) prior to submission for biological testing. Preparative LCMS was performed on a Waters Fraction Lynx system with a Waters MicroMass ZQ mass spectrometer (electrospray ionization) and a single-wavelength UV− visible detector, using acetonitrile/H 2 O gradients with 0.1% formic acid. Fractions were collected on the basis of triggering using UV and mass detection. Yields reported for products obtained by preparative HPLC represent the amount of pure material isolated; impure fractions were not repurified.
6-Bromo-4-chlorocinnoline (8a). In a flame-dried 250 mL roundbottom flask were added 6-bromocinnolin-4(1H)-one (1.00 g, 4.44 mmol), anhydrous tetrahydrofuran (45 mL), and phosphorus oxychloride (1.25 mL, 13.41 mmol). The mixture was refluxed for 1 h at which point a deep green/blue solution had resulted. The solution was cooled to 0°C and was quenched by the dropwise addition of sat. aq. NaHCO 3 (70 mL). The mixture was allowed to warm to room temperature and stir for an additional 1 h. Water (50 mL) was added, and the mixture was extracted with dichloromethane (3 × 100 mL). The combined organic layers were washed with sat. aq. NaHCO 3 (50 mL), washed with brine (50 mL), dried over Na 2 SO 4 , concentrated on to silica, and purified by flash column chromatography using a gradient of 1−5% methanol in dichloromethane to yield an inseparable 10:1 mixture of 8a and 8b as a brown solid in 85% yield. 1 7-Bromo-4-chlorocinnoline (8c). In a flame-dried 25 mL roundbottom flask were added 7-bromocinnolin-4(1H)-one (166 mg, 0.74 mmol), anhydrous tetrahydrofuran (7 mL), and phosphorus oxychloride (0.2 mL, 2.15 mmol). The mixture was refluxed for 1 h at which point a deep green/blue solution had resulted. The solution was + . 7-Bromo-1-chlorophthalazine (9a). In a flame-dried 25 mL roundbottom flask were added 7-bromophthalazin-1(2H)-one (205 mg, 0.91 mmol), anhydrous acetonitrile (9 mL), and phosphorus oxychloride (0.3 mL, 3.22 mmol). The mixture was refluxed for 2 h, then cooled to 0°C, diluted with dichloromethane (20 mL), and quenched with a dropwise addition of sat. aq. NaHCO 3 (20 mL). The biphasic mixture was stirred vigorously and allowed to warm to room temperature. After 1 h, the layers were separated and the aqueous was extracted with dichloromethane (2 × 30 mL). The combined organic layers were washed with sat. aq. NaHCO 3 (25 mL), washed with brine (20 mL), dried over Na 2 SO 4 , and concentrated to yield 9a as an orange solid in 91% yield. + . 6-Bromo-1-chlorophthalazine (9c). In a flame-dried 50 mL roundbottom flask were added 6-bromophthalazin-1(2H)-one (402 mg, 1.78 mmol), anhydrous acetonitrile (18 mL), and phosphorus oxychloride (0.5 mL, 5.36 mmol). The mixture was refluxed for 2 h, then cooled to 0°C, diluted with dichloromethane (40 mL), and quenched with a dropwise addition of sat. aq. NaHCO 3 (40 mL). The biphasic mixture was stirred vigorously and allowed to warm to room temperature. After 1 h, the layers were separated, and the aqueous was extracted with dichloromethane (2 × 50 mL). The combined organic layers were washed with sat. aq. NaHCO 3 (40 mL), washed with brine (30 mL), dried over Na 2 SO 4 , and concentrated to yield 29c as a yellow solid in 94% yield. 6-Bromocinnolin-4(1H)-one (15) . In a 250 mL round-bottom flask were added 1-(2-amino-5-bromophenyl)ethanone (8.34 g, 39.0 mmol), water (30 mL), and conc. hydrochloric acid (30 mL, 987 mmol). The mixture was cooled to 0°C in an ice bath and allowed to stir for 15 min until a suspension resulted. Aqueous sodium nitrite (2 M, 20 mL, 40.0 mmol) was then added dropwise with an addition funnel. The resulting solution was allowed to warm to room temperature over 1.5 h and was stirred at room temperature overnight, then refluxed for 6 h. The mixture was cooled to room temperature, water (200 mL) was added, and the mixture was extracted with ethyl acetate (3 × 200 mL). The combined organic layers were then washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated onto silica. The crude product was then purified by flash column chromatography using a gradient of 1−10% methanol in dichloromethane to yield 15 as a dark brown solid in 82% yield. 1 (18) . In a 50 mL round-bottom flask were added 1-(2-amino-4-bromophenyl)ethanone (712 mg, 3.33 mmol), water (3 mL), and conc. hydrochloric acid (3 mL, 99 mmol). The mixture was cooled to 0°C in an ice bath and allowed to stir for 15 min until a suspension resulted. Aqueous sodium nitrite (2 M, 1.84 mL, 3.68 mmol) was then added dropwise with an addition funnel. The resulting solution was allowed to warm to room temperature over 1.5 h and was stirred at room temperature overnight, then refluxed for 6 h. The mixture was cooled to room temperature, water (35 mL) was added, and the mixture was extracted with ethyl acetate (3 × 40 mL). The combined organic layers were then washed with brine (20 mL), dried over sodium sulfate, filtered, and concentrated onto silica. The crude product was then purified by flash column chromatography using a gradient of 20 + . 6-Bromoisobenzofuran-1(3H)-one (20a). In a 100 mL roundbottom flask was dissolved isobenzofuran-1(3H)-one (4.01 g, 29.9 mmol) in trifluoroacetic acid (14 mL, 182 mmol) and sulfuric acid (6.5 mL, 122 mmol). N-Bromosuccinimide (7.95 g, 1.49 mmol) was added portionwise over 8 h, and the solution was stirred at room temperature for an additional 87 h. The solution was diluted with water (40 mL) and ethyl acetate (40 mL). The pH of the aqueous layer was neutralized with 1 M aq. NaOH and sat. aq. NaHCO 3 . The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with brine (25 mL), dried over Na 2 SO 4 , and concentrated onto silica. The crude product was then purified by flash column chromatography using 10−20% ethyl acetate in hexanes to yield 20a as white solid in 57% yield. 1 + . 3,6-Dibromoisobenzofuran-1(3H)-one (21a). In a 50 mL roundbottom flask were added 6-bromoisobenzofuran-1(3H)-one (1.00 g, 4.69 mmol), N-bromosuccinimide (958 mg, 5.38 mmol), 2,2′-azobis(2-methylpropionitrile) (75 mg, 0.46 mmol), and chloroform (23 mL). The mixture was refluxed for 2.5 h, then cooled to room temperature and quenched with sat. aq. NaHCO 3 (25 mL). The organic layer was removed, washed with water (20 mL), washed with brine (15 mL), and concentrated onto silica. The crude product was purified by flash column chromatography using a gradient of 5−10% ethyl acetate in hexanes to yield 21a as a white solid in 61% yield. 
3,5-Dibromoisobenzofuran-1(3H)-one (21b).
In a 25 mL roundbottom flask were added 5-bromoisobenzofuran-1(3H)-one (499 mg, 2.34 mmol), N-bromosuccinimide (421 mg, 2.37 mmol), 2,2′-azobis(2-methylpropionitrile) (38 mg, 0.23 mmol), and chloroform (10 mL). The mixture was refluxed for 2.5 h, then cooled to room temperature and quenched with sat. aq. NaHCO 3 (10 mL). The organic layer was removed, washed with water (10 mL), washed with brine (5 mL), and concentrated onto silica. The crude product was purified by flash column chromatography using 10% ethyl acetate in hexanes to yield 21b as a white solid in 49% yield. 1 
7-Bromophthalazin-1(2H)-one (22a).
In a 25 mL round-bottom flask was dissolved 3,6-dibromoisobenzofuran-1(3H)-one (143 mg, 0.49 mmol) in ethanol (5 mL). Hydrazine monohydrate (0.12 mL, 2.48 mmol) was then added via a syringe, and the solution was refluxed for 1.5 h. The solution was cooled to room temperature, and ice water (15 mL) was added to the reaction mixture. The precipitate was vacuum filtered and dried under a vacuum overnight to yield 22a as a white solid in 56% yield. 
6-Bromophthalazin-1(2H)-one (22b).
In a 25 mL round-bottom flask was dissolved 3,5-dibromoisobenzofuran-1(3H)-one (302 mg, 1.04 mmol) in ethanol (10 mL). Hydrazine monohydrate (0.25 mL, 5.18 mmol) was then added via a syringe, and the solution was refluxed for 1.5 h. The solution was cooled to room temperature, and ice water (30 mL) was added to the reaction mixture. The precipitate was vacuum filtered and dried under a vacuum overnight to yield 22b as a white solid in 73% yield. 1 equiv) . The resulting mixture was refluxed overnight. The formed precipitate was collected by vacuum filtration to obtain the desired products.
General procedure B for the Amination of 4-Chloroquinolines and 1-Chloroisoquinolines. To a solution of the appropriate aryl chloride (1 equiv) in 2-propanol (0.15 M) was added 3-chloro-4-((3-fluorobenzyl)oxy)aniline or 4-(benzyloxy)-3-chloroaniline (1.1 equiv). The resulting mixture was refluxed overnight. The mixture was diluted with water, basified with 3 M aq. NaOH to pH 12, and extracted with dichloromethane (3×). The combined organic layers were washed with water, washed with brine, dried over Na 2 SO 4 , and concentrated. The crude products were purified by flash column chromatography to obtain the desired products.
General Procedure C for the Amination of 4-Chlorocinnolines. A solution of the appropriate 4-chlorocinnoline (1 equiv) and 3-chloro-4-((3-fluorobenzyl)oxy)aniline or 4-(benzyloxy)-3-chloroaniline (4 equiv) in toluene (0.1 M) was refluxed for 2.5 h and cooled to room temperature. Triethylamine (4 equiv) was added, and the mixture was returned to reflux for an additional 30 min. The mixture was cooled back to room temperature, and the formed yellow precipitate was vacuum filtered, washed with ethyl acetate, concentrated onto silica, and purified by flash column chromatography.
General Procedure D for the Amination of 1-Chlorophthalazines. A solution of the appropriate 1-chlorophthalazine (1 equiv) and 3-chloro-4-((3-fluorobenzyl)oxy)aniline or 4-(benzyloxy)-3-chloroaniline (4 equiv) in anhydrous toluene (0.2 M) was heated at 50°C overnight. Water was added, and the mixture was neutralized with 1 M aq. NaOH and was extracted with 5% methanol in dichloromethane. The combined organic layers were washed with brine, dried over Na 2 SO 4 , concentrated onto silica, and purified by flash column chromatography. General Procedure A for Suzuki Couplings. In a 2−5 mL microwave vial equipped with a stir bar were added aryl bromide (1 equiv), boronic ester (1.3 equiv), 1:1 water/ethanol (0.04 M), triethylamine (3 equiv), and palladium(II) acetate (0.01 M in acetone, 1 mol %). The vial was sealed with a septum, and the contents were irradiated to and held at 120°C with stirring for 1 h. The reaction mixture was cooled to room temperature, diluted with water (8 mL), and extracted with dichloromethane (3 × 8 mL). The combined organic layers were washed with aq. NaOH (1 M, 2 × 5 mL), water (5 mL), and brine (5 mL). The organic layer was then dried over Na 2 SO 4 and concentrated onto silica. The crude product was purified by flash column chromatography.
6-Bromo-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)quinolin-4-amine (23)
General Procedure B for Suzuki Couplings. In a 2−5 mL microwave vial equipped with a stir bar were added aryl bromide (1 equiv), boronic ester (1.3 equiv), 1:1 water/ethanol (0.04 M), triethylamine (3 equiv), and bis(triphenylphosphine)palladium(II) chloride (2.5 mol %). The vial was sealed with a septum, and the contents were irradiated to and held at 120°C with stirring for 1 h. The reaction mixture was cooled to room temperature, diluted with water (8 mL), and extracted with dichloromethane (3 × 8 mL). The combined organic layers were washed with aq. NaOH (1 M, 2 × 5 mL), water (5 mL), and brine (5 mL). The organic layer was then dried over Na 2 SO 4 and concentrated on to silica. The crude product was purified by flash column chromatography.
General Procedure C for Suzuki Couplings. In a 2−5 mL microwave vial equipped with a stir bar were added aryl bromide (1 equiv), boronic ester (1.3 equiv), 1:1 water/ethanol (0.04 M), triethylamine (3 equiv), and palladium(II) acetate (5 mol %). The vial was sealed with a septum, and the contents were irradiated to and held at 120°C with stirring for 3 h. The reaction mixture was cooled to room temperature, diluted with water (8 mL), and extracted with dichloromethane (3 × 8 mL). The combined organic layers were washed with aq. NaOH (1 M, 2 × 5 mL), water (5 mL), and brine (5 mL). The organic layer was then dried over Na 2 SO 4 and concentrated on to silica. The crude product was purified by flash column chromatography.
General Procedure D for Suzuki Couplings. To a solution of the appropriate aryl iodide (1 equiv) in 3:2 dimethoxyethane/ethanol (0.05 M) were added the appropriate aryl boronic ester (1.1 equiv), aq. 2 M Na 2 CO 3 (6 equiv), and Pd(PPh 3 ) 4 (5 mol %). The mixture was purged with nitrogen and heated at 85°C for 7 h. The mixture was cooled to room temperature and filtered, and the filtrate was concentrated. The residue was dissolved in ethyl acetate, washed with water, washed with brine, dried over Na 2 SO 4 , and purified by flash column chromatography.
General Procedure E for Suzuki Couplings. To a solution of the appropriate aryl bromide (1 equiv) in 3:2 dimethoxyethane/ethanol (0.05 M) were added the appropriate aryl boronic ester (1.2 equiv), aq. 2 M Na 2 CO 3 (6 equiv), and Pd(PPh 3 ) 4 (7 mol %). The mixture was heated at 85°C for 12 h, then cooled to room temperature, and the solvents were removed under reduced pressure. The residue was purified by silica column chromatography (hexanes/ethyl acetate) and then by reverse phase chromatography (water/acetonitrile) unless otherwise mentioned. 
